| Literature DB >> 28298905 |
Li Huang1, Hui Yuan1, Ma-Feng Liu2, Xin-Xin Zhao2, Ming-Shu Wang2, Ren-Yong Jia1, Shun Chen2, Kun-Feng Sun2, Qiao Yang2, Ying Wu2, Xiao-Yue Chen1, An-Chun Cheng1, De-Kang Zhu3.
Abstract
Riemerella anatipestifer causes serositis and septicaemia in domestic ducks, geese, and turkeys. Traditionally, the antibiotics were used to treat this disease. Currently, our understanding of R. anatipestifer susceptibility to chloramphenicol and the underlying resistance mechanism is limited. In this study, the cat gene was identified in 69/192 (36%) R. anatipestifer isolated from different regions in China, including R. anatipestifer CH-2 that has been sequenced in previous study. Sequence analysis suggested that there are two copies of cat gene in this strain. Only both two copies of the cat mutant strain showed a significant decrease in resistance to chloramphenicol, exhibiting 4 μg/ml in the minimum inhibitory concentration for this antibiotic, but not for the single cat gene deletion strains. Functional analysis of the cat gene via expression in Escherichia coli BL21 (DE3) cells and in vitro site-directed mutagenesis indicated that His79 is the main catalytic residue of CAT in R. anatipestifer. These results suggested that chloramphenicol resistance of R. anatipestifer CH-2 is mediated by the cat genes. Finally, homology analysis of types A and B CATs indicate that R. anatipestifer comprises type B3 CATs.Entities:
Keywords: Riemerella anatipestifer; antibiotics resistance; chloramphenicol acetyltransferase; homologous recombination; site-directed mutagenesis
Year: 2017 PMID: 28298905 PMCID: PMC5331189 DOI: 10.3389/fmicb.2017.00297
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Strains and plasmids used in this study.
| Serotype 6 | ATCC | |
| Serotype 2 | Laboratory collection | |
| RA-CH2Δ1769 | RA-CH2Δ1769, SpcR | This study |
| RA-CH2Δ1772 | RA-CH2Δ1772, CfxR | This study |
| RA-CH2Δ1769Δ1772 | RA-CH2Δ1769Δ1772, SpcR CfxR | This study |
| RA-ATCC11845 (pLMF02) | This study | |
| RA-ATCC11845 (pLMF02:: | This study | |
| RA-ATCC11845 (pLMF02:: | This study | |
| X7232 | Roland et al., | |
| X7232 (pRE112:: 1769USD) | This study | |
| X7232 (pRE112:: 1772UCD) | This study | |
| X7213 | Roland et al., | |
| X7213 (pRE112:: 1769USD) | This study | |
| X7213 (pRE112:: 1772UCD) | This study | |
| BL21(DE3) | Laboratory collection | |
| BL21(DE3) (pET30a) | This study | |
| BL21(DE3) (pET30a:: | This study | |
| BL21(DE3) (pET30a:: | This study | |
| S17-1 | Miller and Mekalanos, | |
| S17-1 (pLMF02) | S17-1 carrying pLMF02, AmpR CfxR | This study |
| S17-1 (pLMF02:: | S17-1 carrying pLMF02:: | This study |
| S17-1 (pLMF02:: | S17-1 carrying pLMF02:: | This study |
| pET30a | pBR322 lacZ, IPTG-inducible promoter, KanR | Laboratory collection |
| pET30a:: | pET30a carrying | This study |
| pET30a:: | pET30a carrying | This study |
| pLMF02 | shuttle vector transferred between | Liu et al., |
| pLMF02:: | pLMF02 carrying | This study |
| pLMF02:: | pLMF02 carrying | This study |
| pYES1new | YAC-BAC shuttle plasmid with SpcR | Laboratory collection |
| pRE112 | sacB mobRP4 R6K ori CmR,pRE112-T-vector | Laboratory collection |
| pRE112:: 1769USD | pRE112 carrying 1769USD from | This study |
| pRE112:: 1772UCD | pRE112 carrying 1772UCD from | This study |
ATCC: American Type Culture Collection.
Primers used in this study.
| 1769up-F | 5′-ATTCCAGTTTTTCAAATTCAATTCTTCCCTA-3′ | This study |
| 1769up-R | 5′-CTGTCCTGGCTGGTATTTAACATATTTAATTTACA-3′ | This study |
| Spc-F | 5′-ATATGTTAAATACCAGCCAGGACAGAAATGCC-3′ | This study |
| Spc-R | 5′-CTTCTTTTTATTATTTGCCGACTACCTTGGTGA-3′ | This study |
| 1769down-F | 5′-CGGCAAATAATAAAAAGAAGGTTCCGAAAT-3′ | This study |
| 1769down-R | 5′-TTGATGTGGCATTTGCCTGCAGAT-3′ | This study |
| 1769Ident-F | 5′-TTTGCGAAGAAGCGGGCTAA-3′ | This study |
| 1769Ident-R | 5′-CAAAGAGTTCCTCCGCCGCT-3′ | This study |
| 1769Big-F | 5′-TACTTAACCCGCCATTTTGCCA-3′ | This study |
| 1769Big-R | 5′-AACGGTAGCAACCCAAGCAGTG-3′ | This study |
| 1772up-F | 5′-ATTCTCCAGAGTCGGATTCTGTTGAATTTTTTA-3′ | This study |
| 1772up-R | 5′-GCTTCGGGGTCATTATATATTTAACATATTTAATTTACAAT-3′ | This study |
| Cfx-F | 5′-ATATGTTAAATATATAATGACCCCGAAGCAGGGT-3′ | This study |
| Cfx-R | 5′-GAACCTTCTTTTTATTAAGATTTTACTGAAGTTTGCATT-3′ | This study |
| 1772down-F | 5′-TTCAGTAAAATCTTAATAAAAAGAAGGTTCCGAAATTC-3′ | This study |
| 1772down-R | 5′-TCTAATAAACGATTTTTGGTGGGACACAACTTAC-3′ | This study |
| 1772Ident-F | 5′-ATTTTGACGGATTTATTAGTTGTT-3′ | This study |
| 1772Ident-R | 5′-TTCCGTATAAGCTATCTGAAAACT-3′ | This study |
| 1772Big-F | 5′-AATTTTGAACTTAACCCGCC-3′ | This study |
| 1772Big-R | 5′-ACTACGTCGTACAACATCGTATTG-3′ | This study |
| 16SrRNA-F | 5′-CGAAAGTGATAAGTTAGCCACCT-3′ | This study |
| 16SrRNA-R | 5′-GCAGCACCTTGAAAATTGTCC-3′ | This study |
| cat-F1/ MF1 | 5′-GGGAATTCCATATGAAAAATTTCTTCGAAAGTC-3′ | This study |
| cat-R1/MR2 | 5'-CCGCTCGAGTCAGTGGTGGTGGTGGTGGTGTTTCATTTTTCTAAAAAACTT-3′ | This study |
| MR1 | 5′-ATATTTAGCACCTTGATTACCTG -3′ | This study |
| MF2 | 5′-GTAATCAAGGTGCTAAATATGATT-3′ | This study |
| cat-F2 | 5′-CATGCCATGGATGAAAAATTTCTTCGAAAGTC-3′ | This study |
| cat-R2 | 5′-CCGCTCGAGTCATTTCATTTTTCTAAAAAACTT-3′ | This study |
Minimal inhibitory concentration (MIC) of chloramphenicol on .
| RA-CH-2 | 32 |
| RA-CH2Δ1769 | 64 |
| RA-CH2Δ1772 | 32 |
| RA-CH2Δ1769Δ1772 | 4 |
| RA-ATCC11845(pLMF02) | <2 |
| RA-ATCC11845(pLMF02:: | 32 |
| RA-ATCC11845(pLMF02:: | <2 |
Figure 1Real-time RT-PCR analysis of . The changes of mRNAs were expressed as fold expression and calculated using the comparative CT (2−ΔΔCT) method. The error bars represent the standard deviation of three independent experiments.
Figure 2mRNA level of . The changes of mRNAs were expressed as fold expression and calculated using the comparative CT (2−ΔΔCT) method. The error bars represent the standard deviation of three independent experiments.
Figure 3Sequence alignments of CAT from .
The CAT and CAT.
| CAT | 8.75 | 8.25 | 8.0 | 8.33 ± 0.38 |
| CATH79A | 0 | 0 | 0 | 0 |
Figure 4Homology analysis of types A and B CATs based on amino acid identity using DNAMAN 8.0 (Lynnon-Biosoft, Ontario, Canada). The sequence information of types A and B CATs are listed in the Supplementary Table .